Effect of NF‑κB inhibitor on high‑mobility group protein B1 expression in a COPD rat model

Wang,Chang‑Ming; Jiang,Ming; Wang,Hui‑Juan

doi:10.3892/mmr.2012.1181

Effect of NF‑κB inhibitor on high‑mobility group protein B1 expression in a COPD rat model

Authors:
- Chang‑Ming Wang
- Ming Jiang
- Hui‑Juan Wang
View Affiliations

Affiliations: Department of Respiratory Disease, The Affiliated Hospital of Guilin Medical College, Guilin 541001, P.R. China
Published online on: November 13, 2012 https://doi.org/10.3892/mmr.2012.1181
Pages: 499-502

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of the nuclear factor‑κB (NF‑κB) inhibitor, pyrrolidine dithiocarbamate (PDTC), on high‑mobility group protein B1 (HMGB1) expression in a rat model of chronic obstructive pulmonary disease (COPD). The COPD model was developed by administering lipopolysaccharides to the airways of rats and smudging (group B). In addition, a model of COPD complicated with hypoxia was established by administering lipopolysaccharides to the airways of rats, smudging and hypoxia (group C). PDTC was administered to the treatment groups by intraperitoneal injection. Reverse transcription polymerase chain reaction (RT‑PCR) and western blot analysis were used to detect the expression of HMGB1 and NF‑κB in lung tissue. RT‑PCR and western blot analysis demonstrated that HMGB1 mRNA and protein expression in groups B and C increased significantly (P<0.05) compared with control group A. In addition, HMGB1 expression in groups B and C gradually increased. HMGB1 mRNA and protein expression in groups B1 and C1 decreased (P<0.05) compared with B and C. NF‑κB protein expression in groups B and C increased significantly (P<0.05) compared with A. NF‑κB protein expression in groups B1 and C1 decreased compared with B and C. Therefore, HMGB1 mRNA and protein expression was identified to be positively correlated with NF‑κB protein expression. The NF‑κB inhibitor, PDTC, was demonstrated to significantly inhibit HMGB1 expression in lung tissues of rats with COPD and this mechanism may be associated with the NF‑κB signal transduction pathway.

View Figures

View References

1	Barbera JA, Peinado VI and Santos S: Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J. 21:892–905. 2003. View Article : Google Scholar : PubMed/NCBI
2	Dorfmuller P, Perros F, Balabanian K and Humbert M: Inflammation in pulmonary arterial hypertension. Eur Respir J. 22:358–363. 2003. View Article : Google Scholar
3	Weitzenblum E, Chaouat A, Canuet M and Kessler R: Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases. Semin Respir Crit Care Med. 30:458–470. 2009. View Article : Google Scholar : PubMed/NCBI
4	Barbera JA and Blanco I: Pulmonary hypertension in patients chronic obstructive pulmonary disease advances in pathophysiology and management. Drugs. 69:1153–1171. 2009. View Article : Google Scholar : PubMed/NCBI
5	Wang H, Yang H and Tracey KJ: Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med. 255:320–331. 2004. View Article : Google Scholar : PubMed/NCBI
6	Grasser M, Lentz A, Lichota J, Merkle T and Grasser KD: The Arabidopsis genome encodes structurally and functionally diverse HMGB-type proteins. J Mol Biol. 358:654–664. 2006.
7	Ferhani N, Letuve S, Kozhich A, et al: Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 181:917–927. 2010. View Article : Google Scholar : PubMed/NCBI
8	Rabe KF, Hurd S, Anzueto A, et al: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 176:532–555. 2007. View Article : Google Scholar : PubMed/NCBI
9	Wouters EF, Groenewegen KH, Dentener MA and Vernooy JH: Systemic inflammation in exacerbation of COPD. Thorac Soc. 4:626–634. 2007. View Article : Google Scholar
10	Gea J, Barreiro E and Orozco-Levi M: Systemic inflammation in COPD. Clin Pulm Med. 16:233–242. 2009. View Article : Google Scholar
11	Yamada S and Maruyama I: HMGB1, a novel inflammatory cytokine. Clin Chim Acta. 375:36–42. 2007. View Article : Google Scholar : PubMed/NCBI
12	Štros M, Bačíková A, Polanská E, Štokrová J and Strauss F: HMGB1 interacts with human to poisomerase alpha and stimulates its catalytic activity. Nucleic Acids Res. 35:5001–5013. 2007.
13	Ferhani N, Letuve S, Kozhich A, et al: Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir and Crit Care Med. 181:917–927. 2010. View Article : Google Scholar : PubMed/NCBI
14	Penzo M, Molteni R, Suda T, et al: Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility group box 1-mediated chemotaxis. J Immunol. 184:4497–4509. 2010. View Article : Google Scholar : PubMed/NCBI
15	Palumbo R, Galvez BG, Pusterla T, et al: Cells migrating to sites of tissue damage in response to the danger signal HMGB1 require NF-kappa B activation. J Cell Biol. 179:33–40. 2007. View Article : Google Scholar : PubMed/NCBI
16	Qin YH, Dai SM, Tang GS, et al: HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. J Immunol. 183:6244–6250. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kew RR, Penzo M, Habiel DM and Marcu KB: The IKKα-dependent NF-κB p52/RelB noncanonical pathway is essential to sustain a CXCL12 autocrine loop in cells migrating in response to HMGB1. J Immunol. 188:2380–2386. 2012.
18	Frenette PS, Mayadas TN, Rayburn H, Hynes RO and Wagner DD: Susceptibility to infection and altered hematopoiesis in mice deficient in both P-and E-selectin. Cell. 84:563–574. 1996. View Article : Google Scholar : PubMed/NCBI
19	Naka Y, Toda K, Kayano K, Oz MC and Pinsky DJ: Failure to express the P-selectin gene or P-selectin blockade confers early pulmonary protection after lung ischemia or transplantation. Proc Natl Acda Sci USA. 94:757–761. 1997. View Article : Google Scholar : PubMed/NCBI
20	Bruck R, Schey R, Aeed H, Hochman A, Genina O and Pines M: A protective effect of pyrrolidine dithiocarbamate in a rat model of liver cirrhosis. Liver Int. 24:169–176. 2004. View Article : Google Scholar : PubMed/NCBI